HBOT Conversations:
Dr. Paul Harch & 8,101 Genes

Dr. Paul G. Harch, M.D. has used hyperbaric oxygen therapy to treat more than 100 different conditions, including stroke, dementia, autism, and traumatic brain injury. His goal is to help his patients get their lives back using hyperbaric oxygen therapy.

He is the author of The Oxygen Revolution and is considered an International expert and pioneer in the field of Hyperbaric Oxygen Therapy (HBOT). His informative, and comprehensive guide on HBOT has helped countless souls better understand what HBOT is and how it directly affects the body at the genetic level.

This episode on 8,101 genes is the eighth in a nine episode series that will be released weekly with Dr. Harch.

Subscribe. Join the discussion. Share the hope.

Watch the Podcast

In episode 8 of 9, host Edward di Girolamo speaks with world renowned HBOT expert, Dr. Paul G. Harch, about aging and the 8,101 genes HBOT affects.

di Girolamo starts this conversation with Dr. Harch bringing up the 8,101 genes that are activated by Hyperbaric Oxygen Therapy.  The discussion leads to talk of Big Pharma, telomeres, reparative gene process, patents, and successful business models for HBOT clinics.

Dr. Harch explains that Hyperbaric Oxygen Therapy affects 8,101 of our genes, and it’s doing so on a different level for the ones that are overactive and abnormal in the disease process. He speaks of a 2004 lecture he gave to A4M about the effects of HBOT on longevity; and asks, “Where is senescence and aging based?”, answering with, “It’s in our DNA”. Dr. Harch dives in to how HBOT turns on our genes to grow new tissue and stimulates cellular repair and regeneration. di Girolamo agrees and brings up a different past lecture from Dr. Harch where Harch referred to Hyperbaric Oxygen Therapy as the ‘Fountain of Youth‘.

This series ends with Dr. Harch discussing a Buffalo VA study, and how the study subjects (comprised of older veterans) literally came alive and started propositioning nurses after Hyperbaric Oxygen Therapy treatments. He explained this is why no follow-up study was ever done because they weren’t expecting such and didn’t know what to do. Makes sense…. studies have shown success in HBOT treating erectile dysfunction.

If you are searching for the Fountain of Youth and ready to activate 8,101 genes in your body —- find a Hyperbaric Oxygen Therapy clinic near you.

Subscribe Now, It’s Free!

[contact-form-7 id="65934" title="Subscribe"]

Guest

Dr. Paul G. Harch

Dr. Paul G. Harch, MD

Dr. Paul G. Harch, M.D. is a clinician in emergency medicine and hyperbaric medicine who is the former director of the University Medical Center Hyperbaric Medicine Department and LSU Hyperbaric Medicine Fellowship. Currently, he is a Clinical Professor of Medicine in the Section of Emergency Medicine at LSU School of Medicine in New Orleans. He graduated from the Johns Hopkins University School of Medicine after graduating from the University of California at Irvine with magna cum laude/Phi Beta Kappa honors.

Dr. Harch initiated and continues to be a private practice that has resulted in the largest case experience in neurological hyperbaric medicine in the world. In this practice, he adapted the concepts of conventional hyperbaric oxygen therapy to wounds in the central nervous system, which spawned the subsequent academic and research practice. Harch HBOT is the best place to receive oxygen therapy treatments, and patients have traveled from more than 50 countries to be treated by Dr. Harch himself.

Harch HBOT – Hyperbaric Oxygen Therapy Clinic

5216 Lapalco Blvd.
Marrero, LA
504-309-4948
hbot@hbot.com
https://hbot.com/

Recent HBOT News

Hyperbaric Oxygen Preconditioning Attenuates Hemorrhagic Transformation Through Reactive Oxygen Species/Thioredoxin-Interacting Protein/Nod-Like Receptor Protein 3 Pathway in Hyperglycemic Middle Cerebral Artery Occlusion Rats.

Abstract: To clarify whether hyperbaric oxygen preconditioning can attenuate hyperglycemia-enhanced hemorrhagic transformation and to establish a role for Nod-like receptor protein 3 inflammasome in the pathophysiology of hemorrhagic transformation. Controlled...

Clinical Trial – The Effects of Height and Weight Adjusted Dose of Local Anesthetic.

At our centre a conventional dose of 12 mg of hyperbaric bupivacaine in combination with a
short acting opioid fentanyl (to increase block density) and a long acting opioid morphine
(to provide post-operative pain relief ) is used for spinal anesthesia for cesarean
section.However, larger doses of local anesthetic drug when used in caesarean section
commonly cause low blood pressure and requires drugs (vasopressors) to treat it. In our study
the investigators will standardize the doses of both opioids (fentanyl/morphine) and adjust
the dose of local anesthetic (bupivacaine) based on the patients height and weight .One of
the obvious challenges anesthesiologists face is providing adequate anesthesia to the patient
whilst minimizing harmful side effects. Our primary concern is the low blood pressure as an
effect of the spinal anesthetic as it is harmful to both mother and the baby. The
investigators propose that the extent of surgical anesthetic block, which is dependent on
height and weight in our adjusted dose group, will provide adequate anesthesia for surgery
and minimise maternal low blood pressure.